NSE · VILINBIO · Pharmaceuticals
Vilin Bio Med Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹42 Cr with net profit ₹2 Cr — a 4.56% net margin, versus 1.46% the period before.
Shareholding
As of 2026-09-30
- Promoter56.65%
- Public43.22%
- FII0.13%
384 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.22× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #22 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹3,03,749 Cr | 88.88 | 16.95 | 18.69% | 27.59% |
| Acutaas Chemicals Limited | ₹33,069 Cr | 75.3 | 17.82 | 23.64% | 27.58% |
| Neuland Laboratories Ltd. | ₹27,043 Cr | 59.76 | 13.33 | 22.3% | 19.61% |
| Jubilant Pharmova Ltd. | ₹15,356 Cr | 39.58 | 2.17 | 5.62% | 4.11% |
| SMS Pharmaceuticals Ltd. | ₹4,758 Cr | 40.68 | 5.65 | 13.88% | 12.04% |
| Aarti Drugs Ltd. | ₹4,631 Cr | 20.1 | 2.75 | 13.61% | 8.03% |
| Hikal Limited | ₹2,743 Cr | 38.56 | 2.32 | 6.03% | -27.19% |
| Beta Drugs Limited | ₹2,021 Cr | 38.93 | 4.62 | 11.86% | 11.69% |
| NGL Fine Chem Limited | ₹1,879 Cr | 29.45 | 5.18 | 17.6% | 11.11% |
| Fermenta Biotech Ltd. | ₹1,395 Cr | 30.04 | 3.33 | 12.29% | 10.01% |
| Vilin Bio Med Limited(this company) | ₹81 Cr | 41.98 | 2.84 | 6.8% | 8.4% |
AI analysis
AI-generated · google/gemini-2.5-flashVilin Bio Med Limited is listed with a market capitalization of Rs 68 Cr. The company reported a revenue of Rs 15.28 Cr and a profit margin of 0% for the most recent period available.
Positives
- +The company's debt-to-equity ratio is 0.2, which indicates a low level of debt.
- +Promoter shareholding is 56.6464%, suggesting a majority stake.
- +The company has no promoter pledged shares, with 0% of promoter holdings pledged.
Negatives
- −The profit margin is 0%, indicating very low profitability on sales.
- −Promoter holding has decreased from 64.5161% in Mar 2024 to 56.6464% in May 2026.
- −Revenue growth information is not available with the provided data.
Financial Performance
Vilin Bio Med Limited reported a revenue of Rs 15.28 Cr for the latest period. Net profit was Rs 0.2235 Cr in Mar 2025, an increase from Rs 0.1624 Cr in Mar 2024. Earnings per share (EPS) for Mar 2025 stood at Rs 0.16, up from Rs 0.12 in the previous year. The company's EBITDA was Rs 1.1509 Cr in Mar 2025.
Profitability & Returns
The company's return on equity (ROE) is 6.8% and return on capital employed (ROCE) is 10.18%. The profit margin is 0%. The earnings per share (EPS) is Rs 1.26 as of the latest data, with a PE ratio of 35.2.
Balance Sheet
Vilin Bio Med Limited has a debt-to-equity ratio of 0.2, indicating a low level of debt relative to equity. The book value per share is Rs 18.6.
Ownership & Pledges
Public shareholding is 43.3536%. There are no shares pledged by the promoters. Over time, promoter holding has decreased from 64.5161% in Mar 2024 to 56.6464% in May 2026.
Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.